CT-measured Muscle Mass Index May Predict Outcomes in IPF Patients, Study Suggests

Months before my idiopathic pulmonary fibrosis (IPF) diagnosis, my wife Rebecca and I met a young engaged couple. Stephanie was a teacher at the school where I worked in Ohio. She’s from Kansas, so I affectionately refer to her as “Dorothy.” Her fiancé, Connor, was in his third year…

Novel selective blockers of the NOX4 enzyme could ease oxidative stress and the subsequent development of fibrosis in lungs and other organs, according to scientists at the University of Arizona. The potential treatments have been licensed to a startup called Fibronox to speed up their development. NOX4, or NADPH…

Upon being diagnosed with idiopathic pulmonary fibrosis (IPF) in 2016, I predicted that many of my relationships would change. What I didn’t know, which might have been the scariest of all the “unknowns,” was how those relationships would change. I often wondered: Will my relationships with my parents get…

Many of us living with chronic illness know the importance of keeping specialist appointments because of the length of time it can take to reschedule them. The decision to cancel a consultation due to unforeseen circumstances can be agonizing. I felt that regret today when I chose to…

In November 2012, I began to experience shortness of breath. My throat and esophagus also felt somewhat cold, like I was breathing and exhaling cold air even when I was in the house. I didn’t think anything of it and didn’t attribute these symptoms to an illness. On a trip…

Lung cancer patients with underlying idiopathic pulmonary fibrosis (IPF) treated with proton radiation therapy live longer than those treated with X-ray irradiation, a study shows. Additionally, fewer occurrences of treatment-related lung complications were reported in proton therapy-treated patients. The study, “Preliminary result of definitive radiotherapy in patients with non-small cell…

Algernon Pharmaceuticals announced its plans to conduct a new in vivo animal study comparing its lead anti-fibrotic NP-251 compound with clinically relevant doses of both Esbriet (pirfenidone) and Ofev (nintedanib), two approved medicines for the treatment of idiopathic pulmonary fibrosis (IPF). IPF is a chronic lung disease characterized by a progressive and irreversible decline in…